Adaptimmune makes board appointment
This article was originally published in Scrip
Executive Summary
Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, has named Lawrence (Larry) Alleva to its board of directors as an independent, non-executive director. Mr Alleva will also serve as chair of the board audit committee. Mr Alleva is a former partner of PricewaterhouseCoopers. He is currently a director for public companies Tesaro and Bright Horizons Family Solutions and for privately held Mirna Therapeutics.